Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the amyloid-targeting Alzheimer’s drug Kisunla, participated in the startup’s new financing.
The post Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders appeared first on MedCity News.